CA2566716C - Prolongation of survival of an allograft by inhibiting complement activity - Google Patents

Prolongation of survival of an allograft by inhibiting complement activity Download PDF

Info

Publication number
CA2566716C
CA2566716C CA2566716A CA2566716A CA2566716C CA 2566716 C CA2566716 C CA 2566716C CA 2566716 A CA2566716 A CA 2566716A CA 2566716 A CA2566716 A CA 2566716A CA 2566716 C CA2566716 C CA 2566716C
Authority
CA
Canada
Prior art keywords
allograft
complement activity
methods
survival
prolongation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2566716A
Other languages
English (en)
French (fr)
Other versions
CA2566716A1 (en
Inventor
Russell P. Rother
Zhen Zhong
Hao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2566716(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CA2566716A1 publication Critical patent/CA2566716A1/en
Application granted granted Critical
Publication of CA2566716C publication Critical patent/CA2566716C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2566716A 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity Expired - Fee Related CA2566716C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14
US60/571,444 2004-05-14
PCT/US2005/017048 WO2005110481A2 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Publications (2)

Publication Number Publication Date
CA2566716A1 CA2566716A1 (en) 2005-11-24
CA2566716C true CA2566716C (en) 2014-12-23

Family

ID=35385551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2566716A Expired - Fee Related CA2566716C (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Country Status (14)

Country Link
US (3) US20090028850A1 (cg-RX-API-DMAC7.html)
EP (4) EP2338511A3 (cg-RX-API-DMAC7.html)
JP (3) JP5161567B2 (cg-RX-API-DMAC7.html)
AU (1) AU2005244012C1 (cg-RX-API-DMAC7.html)
CA (1) CA2566716C (cg-RX-API-DMAC7.html)
DK (1) DK1755674T3 (cg-RX-API-DMAC7.html)
ES (1) ES2528362T3 (cg-RX-API-DMAC7.html)
HK (2) HK1222342A1 (cg-RX-API-DMAC7.html)
IL (2) IL179240A (cg-RX-API-DMAC7.html)
NZ (1) NZ551308A (cg-RX-API-DMAC7.html)
PL (1) PL1755674T3 (cg-RX-API-DMAC7.html)
PT (1) PT1755674E (cg-RX-API-DMAC7.html)
SI (1) SI1755674T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005110481A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
JP5871798B2 (ja) * 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011146395A2 (en) * 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6479974B2 (ja) * 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ, インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
US20180311299A1 (en) * 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
CN120344253A (zh) * 2022-12-08 2025-07-18 诺麦塔制药有限公司 延长移植物和受体存活期的组合物和方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
IL137614A0 (en) 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
ATE449791T1 (de) * 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
MXPA06013463A (es) * 2004-05-17 2007-03-01 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.

Also Published As

Publication number Publication date
JP5161567B2 (ja) 2013-03-13
PL1755674T3 (pl) 2015-05-29
EP3056218A1 (en) 2016-08-17
IL233326A0 (en) 2014-08-31
ES2528362T3 (es) 2015-02-09
HK1201758A1 (en) 2015-09-11
EP2338511A2 (en) 2011-06-29
WO2005110481A3 (en) 2006-06-22
DK1755674T3 (en) 2015-02-09
IL179240A (en) 2014-07-31
HK1222342A1 (en) 2017-06-30
AU2005244012B2 (en) 2011-08-18
US20090028850A1 (en) 2009-01-29
AU2005244012C1 (en) 2013-05-02
SI1755674T1 (sl) 2015-04-30
AU2005244012A1 (en) 2005-11-24
IL179240A0 (en) 2007-03-08
EP1755674B1 (en) 2014-11-19
JP2007537299A (ja) 2007-12-20
WO2005110481A2 (en) 2005-11-24
US20190309053A1 (en) 2019-10-10
AU2005244012B9 (en) 2011-11-03
NZ551308A (en) 2009-06-26
JP2013032391A (ja) 2013-02-14
JP5590624B2 (ja) 2014-09-17
EP1755674A2 (en) 2007-02-28
PT1755674E (pt) 2015-02-05
JP2014080438A (ja) 2014-05-08
HK1101962A1 (en) 2007-11-02
EP2338511A3 (en) 2012-07-25
CA2566716A1 (en) 2005-11-24
US20170267751A1 (en) 2017-09-21
EP2815767A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
SG171578A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
WO2005110481A3 (en) Prolongation of survival of an allograft by inhibiting complement activity
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2009045360A3 (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier
WO2006081510A3 (en) Methods for treating renal cell carcinoma
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
TW200718689A (en) 2-Amino-quinazolin-5-ones
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
WO2006124698A3 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
GEP20115230B (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4
EP2633856A3 (en) ATP citrate lyase inhibitors for treating cancer
WO2007028085A3 (en) Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
WO2004087066A3 (en) Hif-1 inhibitors
WO2005060960A3 (en) Use of histamine to treat bone disease
MXPA05010388A (es) Dispositivos, metodos y composiciones para prevenir la restenosis.
SG155939A1 (en) Phosphoindoles as hiv inhibitors
WO2006047841A3 (en) Engineering with homing factors
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
WO2019173159A8 (en) Ergothioneine compositions and methods for maintaining and/or increasing vitamin c levels in cells and organisms
EP4585223A3 (en) Transplanted cell protection via inhibition of polymorphonuclear cells
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2008008549A3 (en) Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat neoplasia

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831